Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study

Motoshi Ichikawa, Ryujiro Suzuki, Kensuke Kataoka, Yasunobu Noda, Joe Shindoh, Syuichi Matsumoto, Yoshimasa Tanikawa, Kiyoshi Suzuki, Kenji Baba, Yuichiro Shindo, Masashi Kondo, Kazuyoshi Imaizumi, Hiroaki Kume, Yoshinori Hasegawa, Kenzo Takagi, Hiroyuki Taniguchi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33-75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84%) and stage IV disease (81%). The response rate for the first-line chemotherapy was 28%. Paclitaxel was administered at a dose of 80mg/m2 as an intravenous infusion 60min weekly for 6 consecutive weeks of an 8-week cycle. All patients were assessable for response and toxicity. The median number of cycles administered was two (range 1-8), and the overall response rate was 15.6%. The median survival time (MST) was 10.6 months (95% CI=8.2-12.5), while the 1-year survival rate was 37.5%, and the median progression-free survival was 4.9 months (95% CI=3.0-7.1). Hematological toxicities (grade 3 or 4) were observed in 15 patients (46.9%) with leukopenia, and in 4 (12.5%) with anemia. Non-hematological toxicity was generally mild, though grade 3 anorexia was observed in 3 patients (9.3%). No treatment-related deaths were observed. In conclusion, second-line weekly paclitaxel is effective in NSCLC patients treated with docetaxel plus carboplatin and is associated with a tolerable toxicity profile.

Original languageEnglish
Pages (from-to)319-322
Number of pages4
JournalLung Cancer
Volume69
Issue number3
DOIs
Publication statusPublished - 01-09-2010

Fingerprint

docetaxel
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Leukopenia
Anorexia
Intravenous Infusions
Disease-Free Survival
Anemia
Adenocarcinoma
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Ichikawa, Motoshi ; Suzuki, Ryujiro ; Kataoka, Kensuke ; Noda, Yasunobu ; Shindoh, Joe ; Matsumoto, Syuichi ; Tanikawa, Yoshimasa ; Suzuki, Kiyoshi ; Baba, Kenji ; Shindo, Yuichiro ; Kondo, Masashi ; Imaizumi, Kazuyoshi ; Kume, Hiroaki ; Hasegawa, Yoshinori ; Takagi, Kenzo ; Taniguchi, Hiroyuki. / Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin : A multi-center phase II study. In: Lung Cancer. 2010 ; Vol. 69, No. 3. pp. 319-322.
@article{e4a334755dfc4a9db3ea63ffa6fa44c4,
title = "Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study",
abstract = "We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33-75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84{\%}) and stage IV disease (81{\%}). The response rate for the first-line chemotherapy was 28{\%}. Paclitaxel was administered at a dose of 80mg/m2 as an intravenous infusion 60min weekly for 6 consecutive weeks of an 8-week cycle. All patients were assessable for response and toxicity. The median number of cycles administered was two (range 1-8), and the overall response rate was 15.6{\%}. The median survival time (MST) was 10.6 months (95{\%} CI=8.2-12.5), while the 1-year survival rate was 37.5{\%}, and the median progression-free survival was 4.9 months (95{\%} CI=3.0-7.1). Hematological toxicities (grade 3 or 4) were observed in 15 patients (46.9{\%}) with leukopenia, and in 4 (12.5{\%}) with anemia. Non-hematological toxicity was generally mild, though grade 3 anorexia was observed in 3 patients (9.3{\%}). No treatment-related deaths were observed. In conclusion, second-line weekly paclitaxel is effective in NSCLC patients treated with docetaxel plus carboplatin and is associated with a tolerable toxicity profile.",
author = "Motoshi Ichikawa and Ryujiro Suzuki and Kensuke Kataoka and Yasunobu Noda and Joe Shindoh and Syuichi Matsumoto and Yoshimasa Tanikawa and Kiyoshi Suzuki and Kenji Baba and Yuichiro Shindo and Masashi Kondo and Kazuyoshi Imaizumi and Hiroaki Kume and Yoshinori Hasegawa and Kenzo Takagi and Hiroyuki Taniguchi",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.lungcan.2009.11.021",
language = "English",
volume = "69",
pages = "319--322",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Ichikawa, M, Suzuki, R, Kataoka, K, Noda, Y, Shindoh, J, Matsumoto, S, Tanikawa, Y, Suzuki, K, Baba, K, Shindo, Y, Kondo, M, Imaizumi, K, Kume, H, Hasegawa, Y, Takagi, K & Taniguchi, H 2010, 'Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study', Lung Cancer, vol. 69, no. 3, pp. 319-322. https://doi.org/10.1016/j.lungcan.2009.11.021

Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin : A multi-center phase II study. / Ichikawa, Motoshi; Suzuki, Ryujiro; Kataoka, Kensuke; Noda, Yasunobu; Shindoh, Joe; Matsumoto, Syuichi; Tanikawa, Yoshimasa; Suzuki, Kiyoshi; Baba, Kenji; Shindo, Yuichiro; Kondo, Masashi; Imaizumi, Kazuyoshi; Kume, Hiroaki; Hasegawa, Yoshinori; Takagi, Kenzo; Taniguchi, Hiroyuki.

In: Lung Cancer, Vol. 69, No. 3, 01.09.2010, p. 319-322.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin

T2 - A multi-center phase II study

AU - Ichikawa, Motoshi

AU - Suzuki, Ryujiro

AU - Kataoka, Kensuke

AU - Noda, Yasunobu

AU - Shindoh, Joe

AU - Matsumoto, Syuichi

AU - Tanikawa, Yoshimasa

AU - Suzuki, Kiyoshi

AU - Baba, Kenji

AU - Shindo, Yuichiro

AU - Kondo, Masashi

AU - Imaizumi, Kazuyoshi

AU - Kume, Hiroaki

AU - Hasegawa, Yoshinori

AU - Takagi, Kenzo

AU - Taniguchi, Hiroyuki

PY - 2010/9/1

Y1 - 2010/9/1

N2 - We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33-75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84%) and stage IV disease (81%). The response rate for the first-line chemotherapy was 28%. Paclitaxel was administered at a dose of 80mg/m2 as an intravenous infusion 60min weekly for 6 consecutive weeks of an 8-week cycle. All patients were assessable for response and toxicity. The median number of cycles administered was two (range 1-8), and the overall response rate was 15.6%. The median survival time (MST) was 10.6 months (95% CI=8.2-12.5), while the 1-year survival rate was 37.5%, and the median progression-free survival was 4.9 months (95% CI=3.0-7.1). Hematological toxicities (grade 3 or 4) were observed in 15 patients (46.9%) with leukopenia, and in 4 (12.5%) with anemia. Non-hematological toxicity was generally mild, though grade 3 anorexia was observed in 3 patients (9.3%). No treatment-related deaths were observed. In conclusion, second-line weekly paclitaxel is effective in NSCLC patients treated with docetaxel plus carboplatin and is associated with a tolerable toxicity profile.

AB - We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33-75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84%) and stage IV disease (81%). The response rate for the first-line chemotherapy was 28%. Paclitaxel was administered at a dose of 80mg/m2 as an intravenous infusion 60min weekly for 6 consecutive weeks of an 8-week cycle. All patients were assessable for response and toxicity. The median number of cycles administered was two (range 1-8), and the overall response rate was 15.6%. The median survival time (MST) was 10.6 months (95% CI=8.2-12.5), while the 1-year survival rate was 37.5%, and the median progression-free survival was 4.9 months (95% CI=3.0-7.1). Hematological toxicities (grade 3 or 4) were observed in 15 patients (46.9%) with leukopenia, and in 4 (12.5%) with anemia. Non-hematological toxicity was generally mild, though grade 3 anorexia was observed in 3 patients (9.3%). No treatment-related deaths were observed. In conclusion, second-line weekly paclitaxel is effective in NSCLC patients treated with docetaxel plus carboplatin and is associated with a tolerable toxicity profile.

UR - http://www.scopus.com/inward/record.url?scp=77955096246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955096246&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2009.11.021

DO - 10.1016/j.lungcan.2009.11.021

M3 - Article

C2 - 20053476

AN - SCOPUS:77955096246

VL - 69

SP - 319

EP - 322

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -